Volume 27, Issue 2 - Public Disclosure

Editorial

Author: Alison McIntosh

Abstract

Download the full article

References

1. European Medicines Agency Clinical Data website, Available from: https://clinicaldata.ema.europa.eu/web/cdp/home
2. Sharfstein JM, Miller JD, Davis JS, et al. Blueprint for transparency at the U.S. Food and Drug Administration: recommend - ations to advance the development of safe and effective medical products. The Journal of Law, Medicine & Ethics. 2017;45(4 Suppl):7-23. Available from Available from: https://www.jhsph.edu/departments/health-policy-and-management/blueprint-for-transparency-at-the-food-and-drug-administration/1.pdf
3. Public release of clinical information. Health Canada. Current Status: Ongoing technical consultations and public consultation on draft changes to the Food and Drug Regulations and the Medical Device Regulations. Available from Available from: https://www.canada.ca/en/health-canada/programs/consultation-public-release-clinical-information-drug-submissions-medical-device-applications.html?wbdisable=true
4. Drug Approval Package: ERLEADA (apalutamide). Available from Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/Erleada_210951_toc.cfm
5. Hrynaszkiewicz I, Norton ML, Vickers AJ, Altman DG. Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers. Trials. 2010; 11:9.
6. Recommendations for the Conduct, Report ing, Editing, and Publication of Scholarly work in Medical Journals. Dec 2017. Available from: http://www.icmje.org/icmje-recommendations.pdf
7. CORE (Clarity and Openness in Reporting: E3-based) Reference: An Open Access Resource to Support Authoring of Clinical Study Reports for Interventional Studies. 2016. Available from: http://www.core-reference.org/media/1032/core-reference-v1_0.pdf